Zydus Lifesciences

Zydus Lifesciences has received approval from the U.S. Food and Drug Administration for a diabetes drug, marking a significant regulatory milestone for the company’s U.S. business. The clearance allows Zydus to market the product in one of the world’s largest pharmaceutical markets, strengthening its presence in the chronic therapy segment. The approval is expected to support revenue growth and enhance the company’s generics portfolio in the United States.

Zydus Lifesciences has received approval from the U.S. Food and Drug Administration (USFDA) for its new antihypertensive medication, marking a significant milestone in the company’s global expansion strategy. The approval allows Zydus to market the drug in the highly regulated U.S. market, underscoring its commitment to therapeutic innovation and international growth. This launch addresses a critical need in cardiovascular healthcare, particularly for patients managing hypertension.

Pharmaceutical giants Dr. Reddy’s Laboratories and Zydus Lifesciences have initiated voluntary recalls of select drug batches in the United States following notifications from the US Food and Drug Administration (USFDA). The recalls pertain to concerns over quality control and compliance with manufacturing standards, underscoring the regulator’s commitment to patient safety. Affected products include widely used generic medications distributed through multiple channels.

Zydus Lifesciences has secured a No Objection Certificate (NOC) from Health Canada for its innovative smoking cessation aid, marking a significant milestone in the company's global expansion strategy. This regulatory approval paves the way for Zydus to introduce its novel therapeutic option in the Canadian market, where smoking-related health burdens continue to be a major public concern.

Zydus Lifesciences Ltd. has secured final approval from the US Food and Drug Administration (USFDA) to manufacture and market its generic version of Niacin extended-release tablets. The approval covers tablet strengths of 500 mg, 750 mg, and 1,000 mg, aimed at treating various cholesterol-related conditions. With annual sales of USD 5.5 million in the United States, the launch of this product strengthens Zydus’s portfolio in the competitive cardiovascular segment. The tablets will be manufactured at the company's Moraiya facility in Ahmedabad.